What are the diagnostic criteria for eosinophilic granulomatosis with polyangiitis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Diagnostic Approach to EGPA

There are no validated diagnostic criteria for EGPA—diagnosis must be based on highly suggestive clinical features, objective evidence of vasculitis (ideally from histology), ANCA testing, and eosinophilia, while classification criteria should NOT be used as diagnostic tools. 1

Critical Distinction: Classification vs. Diagnosis

The 2023 Nature Reviews Rheumatology guideline explicitly states that classification criteria (including the 1990 ACR criteria and 2022 ACR-EULAR criteria) have established sensitivity and specificity but should NOT be used as diagnostic criteria, as they were not developed for this purpose. 1 This is a common pitfall—clinicians often misuse classification criteria to diagnose individual patients, which is inappropriate.

Core Diagnostic Elements

The diagnosis of EGPA requires integration of three key components:

1. Highly Suggestive Clinical Features

Look for this specific constellation 1:

  • Asthma (present in >90% of patients)

    • Adult-onset
    • Lacks seasonal pattern
    • Progressive worsening over time
  • Eosinophilia (>10% or >1,500 cells/μL)

    • Present in almost all patients
    • Caveat: Can be masked by systemic glucocorticoids 1
  • ENT manifestations (60-80% of patients)

    • Chronic rhinosinusitis with nasal polyps
    • Recurrent polyps after surgical excision
    • Otitis media
  • Vasculitic/organ involvement features:

    • Peripheral neuropathy (50-70%): mononeuritis multiplex pattern, sensory ± motor deficits, axonal damage on nerve conduction studies
    • Lung infiltrates (40-50%): multiple, migratory, glucocorticoid-responsive
    • Skin lesions: palpable purpura (most vasculitis-specific)
    • Cardiac involvement: myocarditis, pericarditis
    • Renal disease: proteinuria, hematuria, kidney failure
    • Gastrointestinal involvement
    • Constitutional symptoms: fatigue, weight loss, myalgia, arthralgia

2. Objective Evidence of Vasculitis

Biopsy is recommended when feasible but is NOT essential for diagnosis. 1 When obtained, look for:

  • Eosinophilic vasculitis
  • Perivascular eosinophilic infiltration
  • Eosinophil-rich granulomatous inflammation
  • Extravascular eosinophils

3. ANCA Testing

  • Present in ~40% of EGPA cases 1
  • Usually MPO-ANCA (not PR3-ANCA)
  • ANCA-positive patients: More vasculitic features (glomerulonephritis, peripheral neuropathy, purpura)
  • ANCA-negative patients: More eosinophilic features (cardiac involvement, gastroenteritis)

Baseline Diagnostic Workup

All patients with suspected EGPA require multidisciplinary evaluation including: 1

  • Complete blood count with differential (eosinophil count)
  • ANCA testing (MPO-ANCA and PR3-ANCA)
  • Comprehensive metabolic panel
  • Urinalysis (proteinuria, hematuria)
  • Chest imaging
  • Cardiac evaluation (ECG, troponin, consider echocardiography/cardiac MRI)
  • Nerve conduction studies if neuropathy suspected
  • Sinus imaging if ENT symptoms present
  • Tissue biopsy when accessible and safe

Understanding Available Criteria Sets (For Context Only)

While these should NOT be used diagnostically, understanding them provides clinical context:

2022 ACR-EULAR Classification Criteria (most recent) 1, 2:

  • Weighted scoring system requiring ≥6 points
  • Positive factors: eosinophil count ≥1×10⁹/L (+5), obstructive airway disease (+3), nasal polyps (+3), extravascular eosinophilic inflammation (+2), mononeuritis multiplex (+1)
  • Negative factors: C-ANCA/PR3-ANCA positivity (−3), hematuria (−1)
  • 85% sensitivity, 99% specificity for classification among vasculitides

1990 ACR Criteria 1:

  • Six items: asthma, eosinophilia >10%, neuropathy, non-fixed lung infiltrates, paranasal sinus abnormalities, histological evidence of extravascular eosinophils
  • ≥4 of 6 criteria: 85% sensitivity, 99.7% specificity for classification

Key Clinical Pitfalls

  1. Do not wait for all "classic" features—EGPA phases often overlap and don't follow a predictable sequence 1

  2. Do not rule out EGPA based on negative ANCA—60% of patients are ANCA-negative 1

  3. Do not dismiss the diagnosis if biopsy is unavailable—highly suggestive clinical features are sufficient 1

  4. Check eosinophil count BEFORE starting glucocorticoids—treatment rapidly suppresses eosinophilia 1

  5. Distinguish EGPA from other eosinophilic disorders—requires comprehensive evaluation of vasculitic features, not just eosinophilia 3

Differential Diagnosis Considerations

Must exclude:

  • Other ANCA-associated vasculitides (granulomatosis with polyangiitis, microscopic polyangiitis)
  • Hypereosinophilic syndromes
  • Parasitic infections
  • Drug-induced eosinophilia
  • Eosinophilic asthma without vasculitis
  • Other systemic vasculitides

Related Questions

In a patient with asthma and suspected eosinophilic granulomatosis with polyangiitis (EGPA) who has recurrent lactic acidosis, what is the appropriate evaluation and management?
What is the recommended treatment approach for a patient with non-severe Granulomatosis with Polyangiitis (GPA) who is Anti-Neutrophil Cytoplasmic Antibodies (ANCA)-positive?
What is the recommended treatment regimen for Churg‑Strauss syndrome (eosinophilic granulomatosis with polyangiitis)?
What is the recommended steroid treatment protocol for eosinophilic granulomatosis with polyangiitis (eGPA)?
What focused history should be obtained for an asthmatic patient with an absolute eosinophil count of 2350 cells/µL to evaluate for eosinophilic granulomatosis with polyangiitis (EGPA) or hypereosinophilic syndrome (HES)?
What is the appropriate workup and management for a patient found to have small kidneys on imaging?
How should I manage a critically ill patient in the ICU with septic shock, including airway protection, lung‑protective ventilation, fluid resuscitation, vasopressor support, antimicrobial therapy, blood product replacement, and organ support?
What type of splint should be used to treat a trigger finger?
Does choline deficiency cause clinically significant impairment of muscle growth in otherwise healthy adults?
What target hemoglobin should be aimed for in a patient with moderate-to-severe aortic stenosis and anemia (Hb 4.3 g/dL) who is in heart failure requiring non‑invasive ventilation (NIV) support?
Does vitamin B6 deficiency cause clinically significant changes in muscle growth?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.